Tag Archive for: abiraterone acetate

Phase 3 Trial: Xaluritamig (AMG 509) Plus Abiraterone in mCRPC

A large international Phase 3 clinical trial  is evaluating a new treatment combination for men with metastatic castration-resistant prostate cancer (mCRPC) who have not yet undergone chemotherapy (in castration resistant settings, prior chemo is allowed). The study is testing xaluritamig (AMG 509) together with abiraterone acetate against the investigator’s choice of standard therapies (docetaxel, cabazitaxel, […]

AMPLITUDE: a Phase 3 Clinical Trial of Niraparib Combined with Abiraterone Acetate for HRR-Deficient Metastatic Castration-Sensitive Prostate Cancer

Another Trial Supports Low-Dose Abiraterone Acetate in mCRPC

This study, published in JCO Global Oncology and focused on abiraterone acetate (AA), a drug used to treat metastatic castration-resistant prostate cancer, suggests that a smaller dose of AA is as effective as the standard dose (we already talked about another study pointing in the same direction in Singapore, but this sample is bigger). The […]

AMPLITUDE Trial Update: Niraparib Plus Abiraterone Shows Promise for HRR-Altered Metastatic Prostate Cancer